Regulus Therapeutics (RGLS) Tops Q4 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. ABBV
4. CL
5. LYB
6. TFII
7. NVT
8. SPY
9. AAPL
10. LITE

Go back to Regulus Therapeutics (RGLS) Tops Q4 EPS by 2c

Regulus Therapeutics (RGLS) PT Raised to $1.37 at BMO Capital, Sees Shares 'Range-Bound'

March 8, 2018 5:52 AM EST

BMO Capital raised its price target on Regulus Therapeutics (NASDAQ: RGLS) to $1.37 (from $1.00) while maintaining a Market Perform rating.

"We believe investor focus will remain on the continued progress of Regulus's pipeline, particularly RG-012 for Alport syndrome where slower-than-expected enrollment and site... More